Literature DB >> 15678081

Effects of statins on vascular function of endothelin-1.

Fatima Mraiche1, Jonathan Cena, Debarsi Das, Bozena Vollrath.   

Abstract

1. Although statins have been reported to inhibit the prepro-endothelin-1 (ET-1) gene transcription in endothelial cells, their effects on the vascular function of ET-1 have not been explored. We, therefore, examined the effects of statins on contraction and DNA synthesis mediated by ET-1 in vascular smooth muscle. The effects of statins on contraction induced by ET-1 were compared to those mediated by noradrenaline (NA) and KCl. 2. Simvastatin (SV) induced a concentration-dependent relaxation of tonic contraction mediated by ET-1 (10 nM) (IC50 value of 1.3 microM). The relaxation was also observed in rings precontracted with NA (0.1 microM) and KCl (60 mM). In contrast, pravastatin did not have any effect on the contractions. 3. Endothelial denudation or pretreatment with L-NAME did not prevent the relaxation, but did reduce the relaxant activity of SV. 4. SV prevented Rho activation caused by ET-1 and KCl in aortic homogenates, as assessed by a Rho pulldown assay. 5. The Rho kinase inhibitor HA-1077 mimicked the effects of SV on tonic contractions induced by ET-1, NA and KCl. 6. Pretreatment with the Kv channels inhibitor, 4-aminopyridine, attenuated the ability of SV to relax contractions mediated by ET-1 and NA. 7. In quiescent VSM cells, SV significantly inhibited DNA synthesis and Rho translocation stimulated by ET-1, as assessed by [3H]thymidine incorporation and Western blot, respectively. 8. Inhibition of Rho geranylgeranylation by GGTI-297, or treatment with HA-1077, mimicked the effects of SV on DNA synthesis stimulated by ET-1. 9. The results show that the statin potently inhibits both ET-1-mediated contraction and DNA synthesis via multiple mechanisms. Clinical benefits of statins may result, in part, from their effects on vascular function of ET-1.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15678081      PMCID: PMC1576052          DOI: 10.1038/sj.bjp.0706114

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  51 in total

Review 1.  Novel approaches to lipid lowering: what is on the horizon?

Authors:  W V Brown
Journal:  Am J Cardiol       Date:  2001-03-08       Impact factor: 2.778

2.  Role for G(12)/G(13) in agonist-induced vascular smooth muscle cell contraction.

Authors:  A Gohla; G Schultz; S Offermanns
Journal:  Circ Res       Date:  2000-08-04       Impact factor: 17.367

Review 3.  Vascular effects of HMG CoA-reductase inhibitors (statins) unrelated to cholesterol lowering: new concepts for cardiovascular disease.

Authors:  A M Lefer; R Scalia; D J Lefer
Journal:  Cardiovasc Res       Date:  2001-02-01       Impact factor: 10.787

4.  The polycationic aminoglycosides modulate the vasoconstrictive effects of endothelin: relevance to cerebral vasospasm.

Authors:  G Wickman; M A Nessim; D A Cook; B Vollrath
Journal:  Br J Pharmacol       Date:  2001-05       Impact factor: 8.739

5.  Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells.

Authors:  T Yada; M Nakata; T Shiraishi; M Kakei
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

6.  Inhibition of rho-associated kinase results in suppression of neointimal formation of balloon-injured arteries.

Authors:  N Sawada; H Itoh; K Ueyama; J Yamashita; K Doi; T H Chun; M Inoue; K Masatsugu; T Saito; Y Fukunaga; S Sakaguchi; H Arai; N Ohno; M Komeda; K Nakao
Journal:  Circulation       Date:  2000-05-02       Impact factor: 29.690

7.  The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals.

Authors:  Y Kureishi; Z Luo; I Shiojima; A Bialik; D Fulton; D J Lefer; W C Sessa; K Walsh
Journal:  Nat Med       Date:  2000-09       Impact factor: 53.440

8.  Coexpression of endothelin-converting enzyme-1 and endothelin-1 in different stages of human atherosclerosis.

Authors:  C Ihling; T Szombathy; B Bohrmann; M Brockhaus; H E Schaefer; B M Loeffler
Journal:  Circulation       Date:  2001-08-21       Impact factor: 29.690

9.  Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells.

Authors:  O Hernández-Perera; D Pérez-Sala; E Soria; S Lamas
Journal:  Circ Res       Date:  2000-09-29       Impact factor: 17.367

10.  Characterization of endothelial factors involved in the vasodilatory effect of simvastatin in aorta and small mesenteric artery of the rat.

Authors:  M Alvarez De Sotomayor; M D Herrera; E Marhuenda; R Andriantsitohaina
Journal:  Br J Pharmacol       Date:  2000-11       Impact factor: 8.739

View more
  13 in total

Review 1.  The future of endothelin-receptor antagonism as treatment for systemic hypertension.

Authors:  Gabriel Vorobiof; Burns C Blaxall; John D Bisognano
Journal:  Curr Hypertens Rep       Date:  2006-04       Impact factor: 5.369

2.  A novel mechanism of action for statins against diabetes-induced oxidative stress.

Authors:  C Vecchione; M T Gentile; A Aretini; G Marino; R Poulet; A Maffei; F Passarelli; A Landolfi; A Vasta; G Lembo
Journal:  Diabetologia       Date:  2007-02-06       Impact factor: 10.122

3.  Role of statins in cerebral vasospasm.

Authors:  T Sugawara; R Ayer; J H Zhang
Journal:  Acta Neurochir Suppl       Date:  2008

4.  Severe depressive symptoms are associated with elevated endothelin-1 in younger patients with acute coronary syndrome.

Authors:  Luba Yammine; Lorraine Frazier; Nikhil S Padhye; Matthew M Burg; Janet C Meininger
Journal:  J Psychosom Res       Date:  2014-08-02       Impact factor: 3.006

5.  Tendency to angry rumination predicts stress-provoked endothelin-1 increase in patients with coronary artery disease.

Authors:  Antonio B Fernandez; Robert Soufer; Dorothea Collins; Aaron Soufer; Hooman Ranjbaran; Matthew M Burg
Journal:  Psychosom Med       Date:  2010-04-05       Impact factor: 4.312

6.  Molecular programming of endothelin-1 in HIV-infected brain: role of Tat in up-regulation of ET-1 and its inhibition by statins.

Authors:  Ashok Chauhan; Sven Hahn; Suzanne Gartner; Carlos A Pardo; Senthil Kumar Netesan; Justin McArthur; Avindra Nath
Journal:  FASEB J       Date:  2006-12-28       Impact factor: 5.191

7.  Depression predicts elevated endothelin-1 in patients with coronary artery disease.

Authors:  Matthew M Burg; Elisabeth J Martens; Dorothea Collins; Robert Soufer
Journal:  Psychosom Med       Date:  2010-10-14       Impact factor: 4.312

8.  Three-year change in endothelin-1 and markers of vascular remodelling in a bi-ethnic South African cohort: the SABPA study.

Authors:  C S du Plooy; C M C Mels; H W Huisman; R Kruger
Journal:  J Hum Hypertens       Date:  2017-07-20       Impact factor: 3.012

Review 9.  Statins and vein graft failure in coronary bypass surgery.

Authors:  Marios Margaritis; Keith M Channon; Charalambos Antoniades
Journal:  Curr Opin Pharmacol       Date:  2012-02-10       Impact factor: 5.547

10.  Ggps1 deficiency in the uterus results in dystocia by disrupting uterine contraction.

Authors:  Yong-Juan Sang; Qiang Wang; Feng Zheng; Yue Hua; Xin-Ying Wang; Jing-Zi Zhang; Kang Li; Hai-Quan Wang; Yue Zhao; Min-Sheng Zhu; Hai-Xiang Sun; Chao-Jun Li
Journal:  J Mol Cell Biol       Date:  2021-05-07       Impact factor: 6.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.